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Abstract
The COVID-19 pandemic poses multiple issues of importance to child 
health  including threats to physical health and disruption of in-school learning. 
This  chapter reviews what is currently known about COVID-19  epidemiology, 
 presentation, pathophysiology, case definitions, therapies, and in-school 
 transmission in children.  COVID-19 has some unique characteristics in children 
including the rare yet severe Multisystem Inflammatory Syndrome in Children 
(MIS-C) that may be related to acquired immune responses. There are limited 
studies to date to define therapeutic guidelines in children, however consensus 
recommendations from multiple organizations are summarized including the use 
of immunomodulatory therapies (intravenous immunoglobulin, steroids, anakinra 
and tocilizumab), antiplatelet (aspirin) and anti-coagulant (low molecular 
weight heparin) therapies. Finally, considerations for safe return to the classroom 
are  discussed including strategies for optimized student to teacher ratios, hand 
 washing, social distancing, sibling pairing and staged re-opening strategies.
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1. Introduction
Coronavirus disease (COVID-19) is caused by a virus in the beta-coronavirus 
family, SARS-CoV-2. The specific characteristics of COVID-19 infection in children 
are of particular interest. Little is unknown about the epidemiology of SARS-CoV-2 
transmission in children. The transmissibility of COVID-19 in general is greater than 
other coronaviruses [1]. COVID-19 is typically asymptomatic or presents with mild 
symptoms [1, 2]. Coronavirus causes up to 14% of respiratory infections in children 
however influenza virus infections remain the most common pediatric infections. 
Those most likely to be infected with SARS-CoV-2 are children under three years of 
age [1] and more specifically, children under one year of age. Furthermore, according 
to a metanalysis, 50% of children under the age of five infected with COVID-19 were 
infants under one year of age, male and were exposed to the infection via community 
transmission [3]. This highlights the importance of testing and disease monitoring in 
families with infants and young children.
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COVID-19 disease is less common in children than adults [1, 2]. The lower 
incidence of COVID infection in children may be explained by the lower expres-
sion of Angiotensin Converting Enzyme 2 (ACE2) and TMORSS2 (protease) in 
alveolar epithelial cells in children in comparison to adults and decreased viral 
transmission [2–4]. The higher rates of infection seen in infants may be due to their 
immature immune system, which not only increases their risk of infection, but 
also makes vaccination less effective [1, 3]. Maternal immunization may provide 
maternal-fetal protection [1, 3, 4]. In addition, maternal immunization may protect 
young children as transmission from COVID-positive mothers to children has been 
documented [1, 4]. Therefore, targeted maternal vaccination may be an important 
tool to protect vulnerable infants and children.
2. SARS-CoV-2 overview
Since the discovery of SARS in 2002, including the recent detection of SARS-
CoV-2, seven strains of human coronavirus have been identified, defined by the 
WHO as “A broad family of viruses that cause various conditions, from the common 
cold to more serious illnesses, such as the Middle East respiratory syndrome coro-
navirus and the one that causes severe acute respiratory syndrome.” Among them, 
SARS-CoV-2, the virus responsible for the 2019 coronavirus disease, originated in 
Wuhan (Hubei, China) in December 2019, was declared a pandemic by the WHO 
in March 2020 and is defined as an “enveloped positive-sense single-stranded RNA 
virus 80-220 nm in diameter. The envelope has corona-shaped peaks 20 nm in 
length that resemble the corona of the sun under electron microscopy” [5].
The coronaviral genome encodes four major structural proteins, the spike protein 
(S), the nucleocapsid protein (N), the membrane protein (M), and the envelope 
protein (E), all of which are necessary to produce a structurally complete viral par-
ticle. Unlike the other major structural proteins, N is the only protein that functions 
primarily to bind to the CoV RNA genome, forming the nucleocapsid. Although N 
is largely involved in processes related to the viral genome, it is also involved in other 
aspects of the CoV replication cycle and the host’s cellular response to viral infection 
[6]. Furthermore, protein S plays a crucial role in the entry of the virus into host 
cells and the structural capabilities of this newly discovered SARS-CoV-2 enhance 
its intended actions. Because these prominent peaks are the first point of contact 
with host receptors, therapeutic strategies can be applied to prevent their binding to 
target receptors and prevent viral entry into host cells [7].
The WHO reported that the most common symptoms of COVID-19 are fever, 
dry cough and tiredness. Other less frequent symptoms include nasal congestion, 
headache, conjunctivitis, sore throat, diarrhea, loss of taste or smell, skin rashes 
or changes in the color of the fingers or toes [8]. These symptoms are usually mild 
and begin gradually. Approximately 80% of people recover without the need for 
hospital care, while approximately 1 in 5 people who contract COVID-19 end up 
with severe symptoms and experience breathing difficulties. Elderly people with 
underlying diseases, such as high blood pressure, heart disease, lung problems, 
diabetes or cancer are more likely to suffer from an aggravated clinical stage [8].
The primary route of transmission to humans was zoonotic, via interaction with 
animals. A hypothesis that was later confirmed and defined by the WHO was that 
the virus was spread through droplets that are expelled from the nose or mouth of 
an infected person by coughing, sneezing, or talking, and even by touching infected 
objects and surfaces, such as tables, doorknobs, and railings, so that healthy people 
can become infected if they touch those objects or surfaces and then touch their 
eyes, nose, or mouth [9].
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Kotfis & Skonieczna-Żydecka identified viral cells in gastrointestinal biopsy 
samples, including those that belonged to patients who had left the hospitals, 
which may partially explain gastrointestinal symptoms, potential recurrence, and 
transmission of SARS by persistent shedding in stool as well. Specifically, the virus 
is protein molecule covered by a protective lipid layer that is absorbed into ocular, 
nasal, oral and gastrointestinal mucosal epithelial cells and replicates there [10].
2.1 ACE2: The door to SARS-CoV2
The renin angiotensin aldosterone system (RAAS) is the primary regulator of 
plasma volume, maintaining cardiovascular and fluid homeostasis. This system 
plays a protective and adaptive role against risk phenomena, such as hypotension, 
sodium or water deprivation, and in turn, its dysregulation has implications in the 
development of hypertension and other cardiovascular diseases [11].
Activation of the classic RAAS pathway begins in the juxtaglomerular apparatus 
with the release of preformed renin from its prorenin precursor, secondary to 
baroreflex, beta-adrenergic or molecular stimuli in the macula densa. Renin takes 
the hepatic precursor angiotensinogen and converts it into angiotensin I (Ang I) 
[11]. This decapeptide has no specific known physiological action and ends up 
being converted into octapeptide angiotensin II (Ang II) by angiotensin converting 
enzyme (ACE), which is located primarily in cells of the pulmonary endothelium, 
as well as other tissues [11].
Ang II acts on AT1 receptors and exerts powerful vasoconstrictive, profibrotic 
and proinflammatory effects [6]. The action of Ang II on the AT2 receptor gener-
ates the opposite vasodilator and antiproliferative effect [11].
ACE is an essential component of the renin angiotensin aldosterone system, 
functioning as a transmembrane protein with two N- and C-terminal active 
catalytic domains. The C-terminal domain generates the soluble carboxypeptidase 
that removes the carboxy-terminal dipeptide of Ang I, generating Ang II, while 
hydrolysis of the vasodilator peptides, called bradykinins, occurs by the enzymatic 
action of both domains. ACE2 is a monocarboxypeptidase homologous to ACE 
but has only one transmembrane helix, an intracellular segment, and N- and 
C-terminal domains with a single enzymatic active site, endowing ACE with 
distinct characteristics [11].
ACE2 is also homologous to ACE, which plays a role in the cleavage of angioten-
sin I into angiotensin-(1–9) and the vasoconstrictor peptide angiotensin II in the 
vasodilator angiotensin-(1–7). Consequently, ACE2 acts as the entry point into cells 
for various coronaviruses [12]. By cleaving angiotensin II and increasing vasodilator 
angiotensin-(1–7), it can act as an important regulator of cardiac function and plays 
a protective role in acute lung injury.
Possible antitumor effects of ACE2 and future therapeutic prospects for cancers 
have been reported for ACE2. Unfortunately, ACE2 has a high affinity for severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [7], which may explain its 
manifestations at the respiratory level.
2.2 SARS-CoV-2 and ACE2
Viral infections bind their viral structures with receptors on the host cell surface. 
Although it has been shown that there are several coronaviruses that cause human 
diseases, only three of them bind ACE2: SARS-CoV, SARS-CoV-2 and HCoV-NL63, 
with SARS-CoV being responsible for a health emergency known as severe acute 
respiratory syndrome (SARS) in 2003 in China. Curiously, glycoprotein S is 
characterized as the critical determinant for viral entry into host cells, consisting 
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of two functional subunits, S1 and S2. The S1 subunit recognizes and binds to the 
host receptor through the receptor-binding domain (RBD), while S2 is responsible 
for fusion with the host cell membrane. MERS-CoV uses dipeptidyl peptidase-4 
(DPP4) as an entry receptor, while SARS-CoV and SARS-CoV-2 use ACE2, which is 
abundantly expressed in pulmonary alveolar epithelial cells and enterocytes, sug-
gesting glycoprotein S as a potential drug target to stop SARS-CoV-2 entry [13].
However, SARS-CoV infection downregulates surface expression of the binding 
protein (ACE2), a fundamental component for the entry of the host cell. Low ACE2 
expression is associated with a greater severity of the infection in epithelial cells of 
the human respiratory tract [14].
3. Presentation of COVID-19 in children
The presentation of COVID-19 in children differs somewhat from the presen-
tation seen in adults. COVID-19 in children most commonly present with fever 
and cough [15] and gastrointestinal symptoms such as diarrhea and vomiting. 
Gastrointestinal symptoms are reported in a considerable portion of cases [1, 3, 15] 
which is less characteristic of adult cases. While some patients develop respiratory 
distress syndrome, the severe form of COVID-19 is less common in children as 
compared to adults [15] and the mortality rate of COVID-19 in children is <0.1%. 
COVID-19 infection in children may present with anemia, thrombocytopenia, 
hypoalbuminemia, and altered INR [12]. Other laboratory abnormalities may 
include leukopenia, lymphopenia, increased transaminases and inflammatory 
markers such as procalcitonin and C-reactive protein [1, 16]. While patchy lesions in 
pulmonary lobules of children are identified on chest computed tomographic scans 
with moderate infection, the ground-glass opacities which are a typical feature in 
adults are rare in pediatric patients [15]. The mechanisms underlying the unique 
presentation of COVID-19 in children are unknown and further study is required to 
understand why the presentation differs in children.
IgA antibodies have been found both in Kawasaki disease and in COVID-19 
cases with vasculitis. This suggests that MIS-C could be triggered by a COVID-
19 infection and that similar to Kawasaki disease, IgA antibodies are produced. 
These antibodies have receptors in endothelial, mucosal, and cardiac cells [1]. This 
hypothesis that the vasculitis is mediated by IgA antibodies may explain the simi-
larities between the two pathologies and the potential post-infectious origin [1].
Another common pathology associated with COVID-19 in children is “COVID 
toes”, or chilblains. This primarily affects the toes but can also be seen in the heels 
and fingers, presenting as red-purple, tender, or itchy bumps [17]. The cause 
appears to be the result of vascular damage through the impact of the SARS-CoV-2 
virus on endothelial cells as well as T-cells CD4, CD8, and B-cells [1].
3.1 Multisystem inflammatory syndrome in children (MIS-C)
While most cases of COVID-19 in children range from asymptomatic to mild/
moderate disease, severe disease has been documented in children. Some countries 
have documented cases of COVID-19 in children under the age of five [1, 18] with 
an acute inflammatory syndrome called Multisystem Inflammatory Syndrome 
in Children (MIS-C) [1, 3] that is similar to Kawasaki disease [1, 3, 19] that is a 
medium-vessel vasculitis [1, 18] and typically presents 2 weeks after initial infec-
tion. The most commonly affected vessels in MIS-C are the coronary arteries [20].
Most infants (more than 80%) infected with SARS-CoV-2 develop mild 
COVID-19 with a natural history similar to other self-limited respiratory viruses, 
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without complications [21]. But in the case of children who develop MIS-C, severe 
systemic inflammation occurs with elevated pro-inflammatory cytokines and 
acute phase reactants, affecting multiple organ systems including the gastrointesti-
nal, respiratory, cardiovascular, renal, hepatic, hematological and nervous systems 
among others [22, 23]. The most comprised organ systems include the gastrointes-
tinal, dermatologic and cardiovascular organ systems.
MIS-C typically presents with fever lasting more than 4 days [1, 12, 16] as the 
universal characteristic. Gastrointestinal symptoms [1, 3, 12] may also present as 
the first symptoms [24]. These include abdominal pain, vomiting [1, 3, 12], and 
diarrhea [24]. Neurological symptoms such as headache, sensory disturbances, and 
meningeal signs [1, 24] can also be present. Hemodynamic instability can be present 
as well as cardiovascular complications including heart failure, myocarditis and 
pericarditis. Laboratory values may demonstrate elevations in troponin, proBNP, 
ferritin, C-reactive protein, and D-dimer with neutrophilia and lymphopenia [1, 12, 
16]. Patients may also develop shock [1, 16] with single or multi-organ dysfunction 
requiring intensive care, mechanical ventilation [1, 12] and/or extracorporeal mem-
brane oxygenation (ECMO) [3, 12]. Cytokine storm and ferritin counts >1400 μg/L 
may present in older patients [1]. In summary, MIS-C presents as a hyperinflamma-
tory syndrome with gastrointestinal, neurologic and cardiac manifestations.
3.2 Epidemiology of MIS-C
In April 2020, the United Kingdom reported a series of cases with clinical 
presentation similar to Kawasaki disease (KD), toxic shock syndrome (TSS) and 
hyper-inflammatory state that had an epidemiological link with SARS-CoV-2 [25]; 
since that event, clinically similar cases have been reported in other parts of the 
world, including France, Switzerland, the United States, Canada, Norway, among 
others [18, 26–28]. After the notification of these cases, an expert consensus among 
critical care, infectiology, rheumatology and hematology pediatric subspecialists 
named this new clinical condition “Multisystemic inflammatory syndrome in 
children”.
The worldwide incidence of SARS-CoV-2 in children under 18 years of age is 
322 cases per 100,000 inhabitants and the incidence of MIS-C is 2 per 100,000 
inhabitants [29]. The first cases were reported in the United Kingdom, as well as 
in other places in Europe (France, Germany, Greece, Italy, Luxembourg, Portugal, 
Spain, Switzerland, Sweden), later in Canada and the United States [30]. Most cases 
of MIS-C occur in previously healthy children older than 8 years and adolescents. 
Children of African-American and Latino ancestry are the most affected, in con-
trast to classic KD, which typically affects children under 5 years of age and has a 
higher incidence in East Asia and in children of Asian descent [31].
The first report of MIS-C was a series of 8 cases receiving medical assistance in 
southeast England [25]. Subsequently, 3 series of cases were reported in England 
(n = 58), France and Switzerland (n = 35) and New York (n = 33). In most cases, the 
children were previously healthy, that is, without underlying comorbidities (88% 
in the United Kingdom, 89% in France, and 79% in the New York series) [12, 18]. In 
those with comorbidities, obesity and asthma were the most frequent. The average 
age was 10 years with an age range of 1 to 17 years [32].
To date, the prognostic factors of severe disease in children are not known, 
however, a French prospective study that took data from 397 children admitted for 
COVID-19 in 60 hospitals identified three factors that were independently associ-
ated with severe evolution of the disease in the univariate analysis: age ≥ 10 years 
(OR: 3.4; p = 0.034), hypoxemia (OR: 8.9; p = 0.0004) and C-reactive protein 
≥80 mg / L (OR: 6; p = 0.012) [33]. Meanwhile, research presented at the 2021 
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ENDO Virtual Congress revealed that children with type 1 diabetes whose gly-
cated hemoglobin (A1c) is greater than 9% have a higher risk of severe forms of 
COVID-19 [34]. At the moment many efforts are being carried out in order to better 
characterize the pediatric population at risk, with the aim of identifying susceptible 
populations early and preventing life-threatening events in infants.
3.3 The epidemiology of MIS-C in the Americas
As of January 14, 2021, a total of 17 countries in the Region of the Americas have 
officially notified PAHO / WHO or have published information through an official 
website a total of 2,737 cumulative confirmed cases of MIS-C that coincide chrono-
logically with COVID-19, including 78 deaths [18]. Of the total reported cases, 66% 
were between 0 and 9 years old at the time of illness and only 10% were in the age 
group between 15 and 19 years. Regarding the outcome of these cases, the highest 
proportion of deaths is observed in the age group of 15 to 19 years. Regarding the 
distribution by sex, 56% of the cases are male [35].
The countries with the highest number of confirmed cases are the United 
States with 1,659 cases, Brazil with 631 cases, Chile with 151 cases, the Dominican 
Republic with 102 cases, and Argentina with 65 cases [36]. So far in Colombia, 3 
cases of MIS-C have been identified in the district of Cartagena. These cases were 
detected through media monitoring. The incidence rate of COVID-19 in people 
under 18 years of age per 100,000 inhabitants in Colombia by department, shows 
us that the departments and districts above the 75th percentile are: Amazonas, 
Barranquilla, Atlántico, Bogotá, Cartagena, Chocó, Cesar and Nariño; Between 
the 50 to 75 percentiles are the departments of Valle del Cauca, Cundinamarca, 
Santa Marta, Sucre, Tolima, Bolívar, Magdalena, Antioquia. At the 25th percentile 
are Risaralda, Arauca, Cauca, Santander, Córdoba, Quindío, Caldas and Norte de 
Santander and below the 25th percentile are Boyacá, Guajira, Meta and Huila [37].
3.4 Pathophysiology of MIS-C
MIS-C is a clinically severe event that mimics other pathologies that present 
with hyper-inflammatory status in the pediatric population, in mention: KD, SST, 
Hemophagocytic Lymphohistocytosis (HHL), Macrophage Activation Syndrome 
(SAM), among others [38]. It is characterized by persistent fever (≥38°C) for more 
than 24 hours, with involvement of vital organs and consequent cardiological, 
renal, gastrointestinal, respiratory and / or hematological affection. Patients may 
present with maculopapular rash, arthritis, and aseptic bilateral conjunctivitis, 
similar to KD [39].
Symptoms begin 2 to 6 weeks after the resolution of COVID-19 symptoms (in 
those symptomatic), so it is suggested that it is not due to an effect of the acute 
event, but to an event mediated by the mechanisms of acquired immunity (cellular 
and / or humoral) [40]. In the initial stage, fever is usually documented, accompa-
nied by constitutional symptoms, intense headache, general malaise, irritability, 
GI manifestations such as abdominal pain, vomiting or diarrhea, palmar and / or 
plantar erythema, mucosal edema, among others less frequent [41].
A range of cardiac dysfunctions are commonly seen with MIS-C, including but 
not limited to, myocarditis, pericarditis, aneurysms or dilatation of the coronary 
arteries, valvular insufficiency [1, 16], heart failure [16, 24] and electrocardio-
graphic abnormalities. Other common findings include elevation of troponin, 
proBNP, C-reactive protein, ferritin, IL-6, D-dimer and need for intensive care [12, 
16]. The presence of pericarditis, coronary aneurysms and myocarditis suggest that 
patients with COVID-19 could have an incomplete form of the Kawasaki disease. 
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Immunomodulators used in treatment have yielded positive results restoring 
normal left ventricular function [1] in echocardiographic reports after six weeks of 
treatment.
Subsequently, the patient presents a hyper-inflammatory state, characterized 
by an increase in pro-inflammatory cytokines such as: Interleukin 1 (IL-1), Tumor 
Necrosis Factor alpha (TNF-α), Interleukin 11 (IL-11), Interleukin 12 (IL-12), and 
especially, Interleukin 6 (IL-6) [42]. Proinflammatory cytokines exert a pleio-
tropic and redundant effect, which favors the elevation of acute phase reactants 
and products of the coagulation system, processes termed “immunothrombosis 
and thromboinflammation” [43]. Lactate Dehydrogenase (LDH), Procalcitonin 
(PCT), Globular Sedimentation Rate (ESR), C-Reactive Protein (CRP), Serum 
Ferritin, Serum Amyloid A, Fibrinogen, and D-dimer among other biomarkers 
may elevated. This state can produce functional alterations at the endothelial level, 
generating an imbalance between the homeostatic mechanisms of vasoactive con-
trol, leading to a state of severe hypotension and the consequent cardiogenic shock. 
These conditions may lead to multiple organ failure and death in some cases [44].
Immunologically, the mechanisms underlying the hyperinflammation state 
are not known; however, there are some findings that suggest certain molecular 
and cellular mechanisms. Regarding immunogenetics (Major Histocompatibility 
Complex, MHC, and HLA molecules), Nguyen and Cols, by immunoinformatic 
analysis, examined how HLA variation could affect the cellular immune response 
against coronavirus peptides that infect humans [45]. The researchers found that 
the HLA-B * 46: 01 allele has few SARS-CoV-2 peptide binding sites, while the 
HLA-B * 15: 03 allele showed greater ability to recognize and display highly con-
served peptides in SARS-CoV-2, which suggests that host genetic factors may play 
a role in cellular immune response and clinical presentation in response to SARS-
CoV-2 infection [46].
The superantigen hypothesis has also been proposed to understand and  
clarify the immunological events that support MIS-C [47]. This hypothesis sug-
gests that the SARS-CoV-2 virus produces super antigens that activate the immune 
system. A superantigen refers to peptides (sometimes motifs and / or proteins) that 
bind to T lymphocytes of an individual, expressing a particular group or family of 
genes on the β chain of the variable region (Vβ) of the T-cell receptor (TCR) [48]. 
The binding of the superantigen with the Vβ domains of the TCR leads to their 
polyclonal activation, leading to the production of large amounts of cytokines 
and a clinical syndrome similar to septic shock, similar to what occurs in MIS-C. 
Superantigens are presented to T-cells through binding to non-polymorphic regions 
of HLA-II molecules located on antigen presenting cells (APC) and interact with 
conserved regions of the Vβ domains of the TCR. For example, several  
staphylococcal enterotoxins are SAg [49].
By structure-based computational modeling Rivas and Cols discovered that  
the SARS-CoV-2 Spike (S) protein possesses a high affinity motif located close to 
the S1 / S2 cleavage site with a highly conserved sequence to superantigens [50]. The 
region containing this motif exhibits a high binding affinity to the complementar-
ity determining regions (CDRs) present in the variable domains of the α and β 
chain of the TCR. This region is highly similar to the primary sequence and three-
dimensional structure of a superantigen fragment corresponding to staphylococcal 
enterotoxin B (SEB), which interacts with the TCR and CD28 of T cells [51].
Next-generation immuno-sequencing of the TCR repertoire of COVID-19 
patients indicated that the severity of the infection may be associated with some 
genes that encode the Vβ region of the TCR [52]. Using structure-based compu-
tational modeling, Cheng and cols. Demonstrated that the SARS-CoV-2 protein 
S exhibits a high-affinity TCR-binding motif, being able to form a complex with 
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HLA-II molecules. The researchers argue that this interaction between the virus 
and human T cells could be enhanced by a rare mutation (D839Y / N / E) from a 
European strain of SARS-CoV-2 [52]. The studies also found that the SARS-CoV-2 
protein S possesses a neurotoxin-like sequence motif in the receptor-binding 
domain, which exhibits a high tendency to bind to TCR. These findings are con-
sistent with the clinical presentation of patients with MIS-C, who exhibit hyperin-
flammation and neurological symptoms suggestive of neurotoxicity [53, 54].
3.5 Cases definition
Most children with Covid-19 infection are asymptomatic or present mild 
symptoms, however, children who may develop a significant systemic inflammatory 
response have been identified, which may require hospitalization, ICU admis-
sion and even management for different medical specialties [55]. This syndrome, 
although it is a rare complication, can be fatal in children and adolescents. Due to 
the risk to the health of this population, it is necessary to characterize this disease 
and its risk factors, as well as to initiate immediate epidemiological surveillance. 
WHO has developed a preliminary case definition and case report form for MIS-C 
in children and adolescents. The preliminary case definition reflects the clinical and 
laboratory features observed in children reported to date and are used to identify 
suspected or confirmed cases (Figure 1) [56]. The National Institute of Health of 
Colombia, in its technical document of January 21, 2021, defines the operational 
concepts of cases as follows (Table 1; Figures 2 and 3) [57].
3.6 MIS-C treatment
Currently, studies comparing clinical efficacy of various treatment options are 
lacking. According to the United States Center for Disease Control, Colombian 
Association of Infectious Disease and American College of Rheumatology treatments 
have consisted primarily of supportive care and directed care against the underlying 
inflammatory process. Supportive care may include that may include fluid resuscita-
tion, inotropic support; respiratory support and in rare cases, ECMO [58, 59].
Figure 1. 
Preliminary case definition according to the World Health Organization.
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Anti-inflammatory measures may include the use of intravenous IgG (IVIG) 
and steroids. Aspirin may be used due to concerns for coronary artery involvement 
and antibiotics are sometimes used to treat potential sepsis while awaiting bacterial 
cultures. Thrombotic prophylaxis is often used to treat the hypercoagulable state 
typically associated with MIS-C.
The Colombian Association of Infectious Diseases (CAID) [60] and the 
American College of Rheumatology (ACR) (cite website shown above) have 
provided consensus statements for the management of MIS-C related to the immu-




• Under 18 years of age with fever for >24 hours, current or recent infection for 
SARS-CoV-2 evidenced by RT-PCR or IgM / IgG antibody serology or close contact 
with a COVID-19 confirmed case in the prior 4 weeks.
• Also presenting with any of the following symptoms: abdominal pain, vomiting, 
diarrhea, skin rash, non-purulent bilateral conjunctivitis, erythema on the soles or 
palms or mucosal edema, headache or altered state of consciousness.





• Probable case with clinical findings in at least 2 organ systems (Gastrointestinal 
symptoms: abdominal pain, vomiting, diarrhea or Mucocutaneous; skin rash, 
non-purulent bilateral conjunctivitis, erythema on soles or palms or mucosal 
edema or Neurological symptoms such as headache or conscious state alteration or 
Cardiological symptoms: myocardial dysfunction, pericarditis, abnormalities in the 
coronary arteries or Hematological: evidence of renal or respiratory coagulopathy).
• At least one of these altered laboratory findings: Neutrophilia, thrombocytopenia 
or lymphopenia or elevation of ESR, Fibrinogen, C-reactive protein, Ferritin, 
lactate, D-Dimer, interleukin-6 orThrombocytopenia.
Dismissed MIS-C 
Covid-19 case
None of the conditions listed in the probable or confirmed case definitions are met
Table 1. 
Case definition according to National Institute of health of Colombia.
Figure 2. 
Probable MIS-C COVID-19 case.
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Immunomodulatory management of MISC:
• A stepwise progression of immunomodulatory therapies should be used to 
treat MIS-C with IVIG and/or glucocorticoids considered as first tier  
treatments (ACR)
The use of human polyclonal IVIG at a dose of 2 g / kg is suggested for all 
patients who meet MIS-C diagnostic criteria (CAID) with stable cardiac  
function and fluid status (ACR).
• In patients that do not respond to IVIG the following approaches may be 
considered:
 ○ Low to moderate doses of glucocorticoids may also be considered (ACR) not-
ing that in endemic countries antiparasitic management with albendazole or 
ivermectin is needed to avoid hyperinfestation syndromes of strongyloides 
(CAID).
 ○ The use of a second dose of IVIG at a dose of 2 g / kg in case of no response 
within 36 hours of the first dose, with or without steroid at a low dose 
(prednisolone orally at a maximum of 1 mg / kg / day or its intravenous 
equivalent if there is intolerance to the oral route, according to response) 
may be applied (CAID).
 ○ High dose intravenous pulse glucocorticoids may be considered in shock 
(ACR) such as the administration of pulses of methylprednisolone at 
30 mg / kg / day for 3 days (CAID).
 ○ Children with severe respiratory symptoms due to COVID-19 should be 
considered for immunomodulatory therapy if any of the following are 
present: ARDS, shock/cardiac dysfunction, substantially elevated LDH, 
d-dimer, IL-6, IL-2R, CRP, and/or ferritin levels, and depressed lym-
phocyte count, albumin levels, and/or platelet count (ACR). Risks and 
benefits suggest that anakinra (intravenously or subcutaneously) be used 
as first-line immunomodulatory treatment of children with COVID-19 and 
hyperinflammation (ACR).
Figure 3. 
Confirmed MIS-C COVID-19 case.
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 ○ Tocilizumab may be effective in reducing mortality and intensive care admis-
sion in patients with severe COVID-19 pneumonia and signs of the hyper-
inflammation while causing higher risk for bacterial and fungal infections 
(ACR). When tocilizumab is used to treat children with COVID-19, weight-
based dosing should be employed (body weight < 30 kg, 12 mg/kg IV; body 
weight ≥ 30 kg, 8 mg/kg IV, maximum 800 mg) (ACR). Currently there is no 
evidence to support the benefits of tocilizumab in the pediatric population, 
even in special populations such as cancer patients and patients with primary 
or secondary immunodeficiencies. Current evidence is based on adult patients 
with a therapeutic dose of 8 mg / kg of body weight (requiring a second 
dose 8–24 hours after the first), however, the results have also demonstrated 
adverse events such as gastrointestinal perforation and greater susceptibility 
to secondary infections when used concomitantly with dexamethasone 6 mg 
IV every 24 hours or equivalent corticosteroid dose [58].
• Taper of immunomodulatory medications is recommended in 2–3 weeks after 
recovery (ACR and CAID).
Antiplatelet and Anticoagulation management of MISC:
The use of aspirin at anti-inflammatory doses (3–5 mg / kg / day maximum 
81 mg/day) is recommended in MIS-C (CAID and ACR) in the event of thrombo-
cytosis (≥450,000 / 𝜇L) or dilatation of the coronary arteries until resolution and 
if there is no thrombocytopenia (≤80,000/μl), gastrointestinal bleeding, abnormal 
liver function tests (up to 5 times normal values of transaminases), uncontrolled 
asthma, oral intolerance, or influenza A or B virus infection (CAID). In cases of 
thrombocytosis (platelet count ≥450,000/μl), aspirin should be continued until 
the platelet count normalizes (ACR). Furthermore, patients with MIS-C and 
documented thrombosis or an ejection fraction <35% should receive therapeutic 
anticoagulation with enoxaparin until at least 2 weeks after discharge from the 
hospital (ACR).
4. Back to school
School re-opening is critical to support academic progress, mental health and 
access to essential services. Considerations of transmission and case severity in 
children may guide childcare and school policies. Many countries have reported that 
children under the age of ten have the lowest population based COVID infection 
rates [2]. Furthermore, while serious infections in children under the age of two are 
known to occur [2], studies have shown low infection in schools and low prob-
ability of transmission between children and teachers suggesting that safe school 
re-opening may be possible [60].
Despite uncertainties regarding the safety of returning to the classroom, some 
data collected suggests a partial or total return to face-to-face classes by taking 
measures to reduce community transmission may be possible. Schools in multiple 
countries have already reopened their classrooms with little published evidence 
that schools implementing COVID-19 control policies contribute significantly to 
COVID-19 transmission [61].
Some studies of COVID-19 transmission demonstrate that school-acquired 
infections are limited in comparison to community-acquired infections [62]. For 
example, a case–control study from Mississippi, USA carried out in children over 
18 years of age described a total of 154 with SARS-CoV-2 infections and 243 without 
infection. In this group having attended social gatherings outside the home and 
Primary Care
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receiving visitors was associated with a greater risk of infection, while attending 
school in person was not associated with a greater risk [62].
Despite this promising data, there have been school-related outbreaks. For 
example, in Israel 2 weeks after the reopening of the schools in mid-May 2020 
there was a large outbreak in a high school when 2 students attended school with 
mild symptoms. Students (n = 1,161) and the school staff (n = 151) were tested 
and infection was confirmed in students (n = 153) and staff (n = 25). However, 
some factors reported that may have contributed to this massive outbreak were 
full classrooms with insufficient physical distancing, the lack of mask use in some 
people and the continuous air conditioning that allowed recycle indoor air in closed 
classrooms. Therefore, perhaps implementation of these preventative measures may 
mitigate school transmission [61, 62].
Some measures implemented in schools and nurseries to mitigate the contagion are:
• Use of universal mask
• Adequate physical distancing
• Models of alternation classes (face-to-face-virtual)
• Avoid overcrowding
• Increase air ventilation in classrooms
• Increased coverage of rapid screening tests to quickly isolate asymptomatic 
infected
• Online education options for those who are at higher risk of serious illness or 
death if they contract COVID-19
• Limit groupings in classrooms to a maximum of 10 people
• Thorough cleaning of classrooms before and after activities
• Contingency plan in case someone is exposed to the virus
• Staged re-opening by year groups (eg, primary and secondary) or by geo-
graphic region to allow close monitoring and changes to the re-opening 
strategy as needed [63].
It is important to mention that athletic activities may increase the spread of 
SARS-CoV-2. For example, January 26 the CDC reported an outbreak associated 
with a wrestling tournament in a high school that occurred in December 2020 
including 10 schools and 130 student-athletes, coaches and referees, of the students 
38 (30%) contracted laboratory-confirmed SARS-CoV-2 infection [63]. Contact 
tracing identified 446 contacts of the positive cases that were considered to have 
had a high risk of transmission. One death of reported in one of the contacts of the 
students. However, limitations of the evaluation include that fewer than half of the 
participants were evaluated therefore some cases may have been unrecognized [64].
Simulation models have been used to determine how fast the virus spreads, how 
easily it is contained, effectiveness of containment strategies, social and economic 
impacts of closure, and the role of schools in transmission [63]. For example, some 
simulated transmission control strategies include placing siblings or children who 
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cohabit together in classrooms, assigning one group of children attends face-to-face 
one week while another group interacts online and then switching roles the follow-
ing week, or school closure for 14 days if a symptomatic child attends school with 
those who are asymptomatic returning and symptomatic students staying at home. 
Another simulation evaluated the effect of child-educator ratios per classroom 
including 7: 3, 8: 2 and 15: 2. The most favorable transmission profile was shown 
with 7 students for every 3 educators and group assignment of siblings or students 
who cohabit together [65]. Whereas the worst transmission profile was shown with 
15 students for 2 educators and the random assignment of students [64].
Virtual learning has been used to substitute for in-classroom experiences for many 
children globally. 143 countries had transitioned to online learning by August 2020, 
generating stress for both students and their families [66]. Virtual instruction has 
placed increased demands on family members in terms of time and other resources 
[67]. Fantini et al. suggests that we must take a deep look into the policies that have 
led to the necessary closure of the schools and the impacts they have [2]. The isolation 
school closures cause have great impacts on children, impacting not only their social 
life, but also their identity and personality development. Without proper social inter-
action, children may develop anger, guilt, and even depression in addition to anxiety 
and adjustment disorders. Another consideration is that in the setting of school 
closures students may spend a greater amount of time with their parents. While this 
phenomenon has certain benefits, without the support of schoolteachers, parents 
may become overwhelmed as the only caregivers, potentially exposing children to 
increased domestic violence, especially when parents have financial and mental 
health problems that may be exacerbated by the pandemic [2]. Virtual instruction also 
negatively impacts learning as children are taught best in hands-on learning, espe-
cially when learning to write [2]. Together, these factors illustrate some the hardships 
for children related to the pandemic and school closures.
For these reasons, it is important to implement in-person learning for children 
as part of early recovery. However, precautions should be effectively implemented 
and practiced, that may include social distancing, prevention of shared materials, 
ventilation of spaces, increased hand washing practices and sanitizing availability. 
Control measures include in-person learning could be started through alternating 
face-to-face and virtual learning scheduling to decrease density, the use of masks 
[2] and training of teachers in students in safety procedures [2].
5. The impact of the COVID-19 pandemic in children
The pandemic has affected children in great ways, impacting the way they grow, 
learn, play, and cope with their emotions [4, 60]. Younger children may be most at 
risk from the impacts of COVID-19, as lack of play, exercise, and interaction with 
peers [4, 60] can be affected. Additionally, other symptoms that affect brain devel-
opment, such as stress, isolation, and depression [60], may develop if children wit-
ness friends and family members becoming infected or passing due to COVID-19. 
Children with psychiatric disorders face the greatest challenges, as 50% of psychi-
atric disorders [60] affect children by age 14. It is important to manage symptoms 
presented by these disorders as they may greatly affect child development.
Other symptoms children develop in this health crisis may include trouble 
sleeping and mental health problems. COVID-19 impacts the lives of children in 
various ways and include changing family-life circumstances. Parents might be 
working from home or become unemployed, increasing the risks for drug use and 
abuse in the home. These factors, as well as worries about their own physical health 
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health is affected, they are at risk for post-traumatic stress [60], depression [60], 
and suicide [4, 60].
Important factors for mental health in children include good physical health and a 
good education system. Schools are a valuable resource to provide adequate information 
and help children understand COVID-19. Schools with trained professionals can also 
help identify children with problems and develop therapeutic approaches to support 
them. Teaching children how to cope with their emotions, generate healthy behaviors, 
and allowing children to participate in activities they enjoy are some of the benefits that 
schools can provide to try and counteract problems caused by the pandemic.
6. Conclusion
In conclusion, the COVID-19 pandemic poses some unique challenges for child 
health and learning. In relation to child health, Multisystem Inflammatory Syndrome 
in Children (MIS-C) is a rare but severe complication of COVID-19 related to 
acquired immune responses that requires further research. Despite limited studies to 
date to define therapeutic guidelines in children, consensus recommendations from 
multiple organizations recommend the use of immunomodulatory therapies, anti-
platelet and anti-coagulant therapies. Furthermore, considerations for safe return to 
the classroom such as strategies for optimized student to teacher ratios, hand wash-
ing, social distancing, sibling pairing and staged re-opening strategies may facilitate 
child learning in the setting of this evolving pandemic. Further research into efficacy 
of these proposed interventions will be necessary to inform evidence based guide-
lines for the prevention and management of COVID-19 in children.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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